JP2023052079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023052079A5 JP2023052079A5 JP2022208126A JP2022208126A JP2023052079A5 JP 2023052079 A5 JP2023052079 A5 JP 2023052079A5 JP 2022208126 A JP2022208126 A JP 2022208126A JP 2022208126 A JP2022208126 A JP 2022208126A JP 2023052079 A5 JP2023052079 A5 JP 2023052079A5
- Authority
- JP
- Japan
- Prior art keywords
- hypoimmunogenic
- cell
- cells
- hla
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 306
- 108090000623 proteins and genes Proteins 0.000 claims 108
- 238000000034 method Methods 0.000 claims 87
- 230000014509 gene expression Effects 0.000 claims 52
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 238000012239 gene modification Methods 0.000 claims 33
- 230000005017 genetic modification Effects 0.000 claims 33
- 235000013617 genetically modified food Nutrition 0.000 claims 33
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 30
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 30
- 230000001939 inductive effect Effects 0.000 claims 22
- 102000011727 Caspases Human genes 0.000 claims 18
- 108010076667 Caspases Proteins 0.000 claims 18
- 230000001225 therapeutic effect Effects 0.000 claims 18
- 230000002163 immunogen Effects 0.000 claims 16
- 210000001685 thyroid gland Anatomy 0.000 claims 15
- 230000004077 genetic alteration Effects 0.000 claims 10
- 231100000118 genetic alteration Toxicity 0.000 claims 10
- 210000004413 cardiac myocyte Anatomy 0.000 claims 8
- 230000001332 colony forming effect Effects 0.000 claims 8
- 210000002889 endothelial cell Anatomy 0.000 claims 8
- 230000003511 endothelial effect Effects 0.000 claims 8
- 210000004153 islets of langerhan Anatomy 0.000 claims 8
- 210000003061 neural cell Anatomy 0.000 claims 8
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 8
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 8
- 210000000130 stem cell Anatomy 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 101900095660 Escherichia coli Cytosine deaminase Proteins 0.000 claims 6
- 241000700584 Simplexvirus Species 0.000 claims 6
- 108020004440 Thymidine kinase Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 6
- 229960004413 flucytosine Drugs 0.000 claims 6
- 210000002569 neuron Anatomy 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108010075704 HLA-A Antigens Proteins 0.000 claims 4
- 108010058607 HLA-B Antigens Proteins 0.000 claims 4
- 108010052199 HLA-C Antigens Proteins 0.000 claims 4
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 4
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims 4
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 4
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 3
- 238000006471 dimerization reaction Methods 0.000 claims 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 3
- 229960002963 ganciclovir Drugs 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 101150076800 B2M gene Proteins 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 210000003663 amniotic stem cell Anatomy 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 210000000604 fetal stem cell Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000001178 neural stem cell Anatomy 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 210000001988 somatic stem cell Anatomy 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 238000010459 TALEN Methods 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003516A JP2025069169A (ja) | 2017-01-13 | 2025-01-09 | 免疫工学的な改変をした多能性細胞 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762445969P | 2017-01-13 | 2017-01-13 | |
| US62/445,969 | 2017-01-13 | ||
| PCT/US2018/013688 WO2018132783A1 (en) | 2017-01-13 | 2018-01-14 | Immunoengineered pluripotent cells |
| JP2019538202A JP2020505025A (ja) | 2017-01-13 | 2018-01-14 | 免疫工学的な改変をした多能性細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538202A Division JP2020505025A (ja) | 2017-01-13 | 2018-01-14 | 免疫工学的な改変をした多能性細胞 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003516A Division JP2025069169A (ja) | 2017-01-13 | 2025-01-09 | 免疫工学的な改変をした多能性細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023052079A JP2023052079A (ja) | 2023-04-11 |
| JP2023052079A5 true JP2023052079A5 (https=) | 2023-06-19 |
Family
ID=61148505
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538202A Pending JP2020505025A (ja) | 2017-01-13 | 2018-01-14 | 免疫工学的な改変をした多能性細胞 |
| JP2022208126A Pending JP2023052079A (ja) | 2017-01-13 | 2022-12-26 | 免疫工学的な改変をした多能性細胞 |
| JP2025003516A Pending JP2025069169A (ja) | 2017-01-13 | 2025-01-09 | 免疫工学的な改変をした多能性細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538202A Pending JP2020505025A (ja) | 2017-01-13 | 2018-01-14 | 免疫工学的な改変をした多能性細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003516A Pending JP2025069169A (ja) | 2017-01-13 | 2025-01-09 | 免疫工学的な改変をした多能性細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190376045A1 (https=) |
| EP (1) | EP3568464A1 (https=) |
| JP (3) | JP2020505025A (https=) |
| KR (2) | KR20240095477A (https=) |
| CN (1) | CN110177869A (https=) |
| AU (2) | AU2018207649B2 (https=) |
| BR (1) | BR112019014257A2 (https=) |
| CA (1) | CA3049766A1 (https=) |
| EA (1) | EA201991692A1 (https=) |
| IL (1) | IL267616A (https=) |
| MX (1) | MX2019008413A (https=) |
| WO (1) | WO2018132783A1 (https=) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| CN110177869A (zh) * | 2017-01-13 | 2019-08-27 | 加利福尼亚大学董事会 | 免疫改造的多能细胞 |
| CN110637083A (zh) * | 2017-03-20 | 2019-12-31 | 华盛顿大学 | 细胞及其使用和制备方法 |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| CN120041380A (zh) | 2017-06-12 | 2025-05-27 | 西奈卫生系统公司 | 无需全身性免疫遏制的同种异体移植物耐受 |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US20210308183A1 (en) * | 2018-07-17 | 2021-10-07 | The Regents Of The University Of California | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
| BR112021000637A2 (pt) * | 2018-07-17 | 2021-04-13 | The Regents Of The University Of California | Célula cardíaca hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença cardíaca, método para produzir uma população de células cardíacas hipoimunes, célula endotelial hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença vascular, método para produzir uma população de células endoteliais hipoimunes, neurônio dopaminérgico hipoimune isolado, método para tratar um paciente que sofre de uma doença ou afecção neurodegenerativa, método para produzir uma população de neurônios dopaminérgicos hipoimunes, célula de ilhota pancreática hipoimune isolada, método para tratar um paciente que sofre de diabetes, método para produzir uma população de células de ilhota pancreática hipoimunes, célula de epitélio pigmentado da retina (rpe) hipoimune isolada, método para tratar um paciente que sofre de uma afecção ocular, e método para produzir uma população de células de epitélio pigmentado da retina (rpe) hipoimunes |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| CN113195724A (zh) * | 2018-09-26 | 2021-07-30 | 新加坡国立大学 | 低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒 |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
| CN111424016A (zh) * | 2019-01-09 | 2020-07-17 | 复旦大学 | 降低细胞免疫原性的诱导型多能干细胞系及建立方法 |
| KR20210128440A (ko) * | 2019-02-15 | 2021-10-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 범용 공여자 줄기 세포 및 관련 방법 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2020231882A2 (en) * | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| US12391923B2 (en) | 2019-06-26 | 2025-08-19 | The Regents Of The University Of California | SIRPα-silenced natural killer (NK) cells |
| TW202115245A (zh) * | 2019-06-27 | 2021-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 安全免疫隱形細胞 |
| EP4022037A1 (en) | 2019-07-10 | 2022-07-06 | Helmuth Heinrich Kunz | Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro |
| JP2022543112A (ja) * | 2019-08-01 | 2022-10-07 | サナ バイオテクノロジー，インコーポレイテッド | Ｄｕｘ４発現細胞およびそれらの使用 |
| AU2020336302A1 (en) | 2019-08-23 | 2022-03-03 | Sana Biotechnology, Inc. | CD24 expressing cells and uses thereof |
| KR20220058579A (ko) | 2019-09-05 | 2022-05-09 | 크리스퍼 테라퓨틱스 아게 | 보편적 공여자 세포 |
| US11104918B2 (en) * | 2019-09-05 | 2021-08-31 | Crispr Therapeutics Ag | Universal donor cells |
| CA3153700A1 (en) * | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| WO2021055985A1 (en) * | 2019-09-22 | 2021-03-25 | Cellerant Therapeutics, Inc. | Ipsc-derived, hypoimmunogenic, myeloid progenitor cells |
| JP2022551975A (ja) * | 2019-10-15 | 2022-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｆｃ封鎖を介する移植細胞保護 |
| AU2021207810A1 (en) | 2020-01-13 | 2022-08-04 | Sana Biotechnology, Inc. | Modification of blood type antigens |
| EP4585223A3 (en) | 2020-01-15 | 2025-07-30 | The Regents of the University of California | Transplanted cell protection via inhibition of polymorphonuclear cells |
| CA3165076A1 (en) * | 2020-01-17 | 2021-07-22 | Ryan Clarke | Safety switches for regulation of gene expression |
| MX2022011831A (es) * | 2020-03-25 | 2023-01-04 | Sana Biotechnology Inc | Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas. |
| EP4132544A4 (en) * | 2020-04-06 | 2024-10-23 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND METHODS AND COMPOSITIONS FOR THEIR PRODUCTION |
| EP4138893A4 (en) * | 2020-04-21 | 2024-06-12 | Intima Bioscience, Inc. | CELLULAR VACCINE PLATFORM AND METHODS OF USE THEREOF |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| IL300516A (en) | 2020-08-13 | 2023-04-01 | Sana Biotechnology Inc | Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds |
| CN112342196A (zh) * | 2020-08-18 | 2021-02-09 | 未来智人再生医学研究院(广州)有限公司 | 一种免疫兼容可逆的通用型多能干细胞及其应用 |
| CA3194577A1 (en) * | 2020-10-09 | 2022-04-14 | Sonja SCHREPFER | Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent |
| EP4232468A4 (en) * | 2020-10-20 | 2025-03-19 | Replay Holdings, Inc. | Methods and compositions for cellular therapy |
| CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
| CN114525255A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-11的多能干细胞衍生物及其应用 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN114107211B (zh) * | 2020-12-04 | 2025-09-30 | 未来智人再生医学研究院(广州)有限公司 | 一种多能干细胞及其衍生物 |
| WO2022125439A2 (en) * | 2020-12-07 | 2022-06-16 | The Regents Of The University Of California | Innate immune cell silencing by sirp-alpha engager |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| KR20230146007A (ko) | 2020-12-31 | 2023-10-18 | 크리스퍼 테라퓨틱스 아게 | 범용 공여자 세포 |
| CA3200509A1 (en) | 2020-12-31 | 2022-07-07 | Sonja SCHREPFER | Methods and compositions for modulating car-t activity |
| CA3212370A1 (en) | 2021-03-03 | 2022-09-09 | Sana Biotechnology, Inc. | Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions |
| TW202302839A (zh) * | 2021-03-09 | 2023-01-16 | 國立研究開發法人理化學研究所 | 低免疫原性視網膜色素上皮細胞之製造方法 |
| EP4313087A4 (en) * | 2021-03-30 | 2025-03-19 | The Regents of the University of California | PROTECTION OF TRANSPLANTED CELLS VIA MODIFIED FC RECEPTORS |
| WO2022221699A1 (en) * | 2021-04-16 | 2022-10-20 | Beam Therapeutics, Inc. | Genetic modification of hepatocytes |
| EP4347810A4 (en) * | 2021-05-24 | 2025-06-04 | Sangamo Therapeutics, Inc. | ZINC FINGER NUCLEASES TARGETING CIITA |
| AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
| WO2023008918A1 (ko) * | 2021-07-28 | 2023-02-02 | 의료법인 성광의료재단 | B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법 |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| TW202321435A (zh) | 2021-08-11 | 2023-06-01 | 美商薩那生物科技公司 | 用於改變低免疫原性細胞中之基因表現之可誘導系統 |
| KR20240073006A (ko) | 2021-08-11 | 2024-05-24 | 사나 바이오테크놀로지, 인크. | 동종이계 세포 요법을 위한 유전자 변형된 1차 세포 |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| CN113801881B (zh) * | 2021-08-27 | 2024-02-20 | 浙江大学 | 超级增强子基因序列在促进人b2m基因表达中的用途 |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| MX2024007528A (es) | 2021-12-23 | 2024-08-30 | Sana Biotechnology Inc | Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados. |
| KR20240142624A (ko) * | 2022-01-10 | 2024-09-30 | 사나 바이오테크놀로지, 인크. | 만능줄기세포에서 분화된 면역저하 베타세포 및 관련 용도 및 방법 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| US20250101382A1 (en) | 2022-03-11 | 2025-03-27 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| CN114958768B (zh) * | 2022-06-02 | 2023-03-24 | 健颐生物科技发展(山东)有限公司 | Fgf10旁分泌通用型人成纤维细胞制剂的制备方法 |
| CN117343962A (zh) * | 2022-06-29 | 2024-01-05 | 中国科学院上海营养与健康研究所 | 免疫兼容型人多能干细胞、其制备方法及应用 |
| EP4547825A1 (en) | 2022-07-01 | 2025-05-07 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| CN117384851B (zh) * | 2022-07-11 | 2025-11-21 | 士泽生物医药（苏州）有限公司 | 一种表达faslg的通用型细胞及其制备方法 |
| CN117431217A (zh) * | 2022-07-12 | 2024-01-23 | 上海驯鹿生物技术有限公司 | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 |
| GB202211117D0 (en) * | 2022-07-29 | 2022-09-14 | Replay Holdings Llc | Compositions and methods for non-immunogenecity |
| GB202212144D0 (en) * | 2022-08-19 | 2022-10-05 | Resolution Therapeutics Ltd | Cells for therapy |
| WO2024097315A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Cell therapy products and methods for producing same |
| WO2024107420A1 (en) * | 2022-11-15 | 2024-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine |
| CN118147077B (zh) * | 2022-12-07 | 2025-09-26 | 士泽生物医药（苏州）有限公司 | 一种表达gsn的通用型细胞及其制备方法 |
| CN118207165B (zh) * | 2022-12-07 | 2026-03-20 | 士泽生物医药（苏州）有限公司 | 一种表达stc1的通用型细胞及其制备方法 |
| GB202218755D0 (en) * | 2022-12-13 | 2023-01-25 | Replay Holdings Llc | Compositions and methods for non-immunogenicity |
| JP2026501446A (ja) * | 2022-12-16 | 2026-01-15 | ゼルスマート バイオ‐ファーマシューティカル （スズホウ） シーオー．， エルティーディー． | ユニバーサル細胞及びその製造方法 |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| WO2024169917A1 (zh) * | 2023-02-16 | 2024-08-22 | 士泽生物医药（苏州）有限公司 | 通用型细胞及其制备方法 |
| WO2024229302A1 (en) | 2023-05-03 | 2024-11-07 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
| KR102740042B1 (ko) * | 2023-07-12 | 2024-12-06 | ㈜바이오솔빅스 | 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술 |
| AU2024328949A1 (en) | 2023-08-23 | 2026-03-12 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| CN119351338B (zh) * | 2023-09-15 | 2026-01-23 | 士泽生物医药（苏州）有限公司 | 一种表达cd300ld的低免疫原性细胞及其制备方法 |
| WO2025096757A1 (en) | 2023-11-01 | 2025-05-08 | Sana Biotechnology, Inc. | Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| WO2025230941A1 (en) | 2024-04-30 | 2025-11-06 | Satellite Biosciences, Inc. | Hypoimmunogenic cell mixtures and methods of use thereof |
| WO2025230947A1 (en) | 2024-04-30 | 2025-11-06 | Satellite Biosciences, Inc. | Engineered hepatocytes for secreting polypeptides |
| CN121006322A (zh) * | 2024-05-22 | 2025-11-25 | 上海苹谱医疗科技有限公司 | 一种通用型工程化细胞及其制备方法与应用 |
| WO2025259640A1 (en) * | 2024-06-14 | 2025-12-18 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for bioengineering hypoimmunogenic organs, tissues and cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US20040053836A1 (en) * | 2002-04-22 | 2004-03-18 | Philipp Mayer-Kuckuk | Method for modulating the production of a selected protein in vivo |
| CA2746527A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| DK2438160T3 (en) * | 2009-06-05 | 2016-01-11 | Cellular Dynamics Int Inc | Reprogramming of T cells and hematopoietic cells |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| US20150056225A1 (en) * | 2012-04-17 | 2015-02-26 | University Of Washington Through Its Center For Commercialization | HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof |
| CA2940460A1 (en) * | 2014-03-07 | 2015-09-11 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| EP3134515B1 (en) * | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| KR20170137079A (ko) * | 2015-03-11 | 2017-12-12 | 셀렉티스 | 그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들 |
| EP3294342A4 (en) * | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CN110177869A (zh) * | 2017-01-13 | 2019-08-27 | 加利福尼亚大学董事会 | 免疫改造的多能细胞 |
| WO2020231882A2 (en) * | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
-
2018
- 2018-01-14 CN CN201880006714.XA patent/CN110177869A/zh active Pending
- 2018-01-14 WO PCT/US2018/013688 patent/WO2018132783A1/en not_active Ceased
- 2018-01-14 JP JP2019538202A patent/JP2020505025A/ja active Pending
- 2018-01-14 US US16/476,794 patent/US20190376045A1/en active Pending
- 2018-01-14 EA EA201991692A patent/EA201991692A1/ru unknown
- 2018-01-14 EP EP18702859.2A patent/EP3568464A1/en active Pending
- 2018-01-14 KR KR1020247020089A patent/KR20240095477A/ko active Pending
- 2018-01-14 AU AU2018207649A patent/AU2018207649B2/en active Active
- 2018-01-14 MX MX2019008413A patent/MX2019008413A/es unknown
- 2018-01-14 CA CA3049766A patent/CA3049766A1/en active Pending
- 2018-01-14 KR KR1020197023696A patent/KR20190103373A/ko not_active Ceased
- 2018-01-14 BR BR112019014257-6A patent/BR112019014257A2/pt unknown
-
2019
- 2019-06-24 IL IL267616A patent/IL267616A/en unknown
-
2022
- 2022-12-26 JP JP2022208126A patent/JP2023052079A/ja active Pending
-
2023
- 2023-03-29 US US18/127,936 patent/US20230348862A1/en not_active Abandoned
-
2024
- 2024-10-31 AU AU2024256086A patent/AU2024256086A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003516A patent/JP2025069169A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052079A5 (https=) | ||
| JP2024050597A5 (https=) | ||
| EP4151720B1 (en) | Vcn enhancer compositions and methods of using the same | |
| JP2020523037A5 (https=) | ||
| US20210024884A1 (en) | Safe immuno-stealth cells | |
| JP2020509780A5 (https=) | ||
| JP6066356B2 (ja) | 改善された遺伝子治療方法 | |
| Fan et al. | Stem‐cell challenges in the treatment of Alzheimer's disease: a long way from bench to bedside | |
| JP2020505025A5 (https=) | ||
| IL308706A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| JP2019088334A5 (https=) | ||
| CA3164591A1 (en) | Modification of blood type antigens | |
| US11326183B2 (en) | VCN enhancer compositions and methods of using the same | |
| JP7016556B2 (ja) | 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途 | |
| JP2024527634A (ja) | 酸化ストレス抵抗性を有する間葉系幹細胞、この製造方法および用途 | |
| Zhu et al. | Neuroprotective effects of human umbilical cord-derived mesenchymal stem cells from different donors on spinal cord injury in mice | |
| Chew et al. | Gene-agnostic approaches to treating inherited retinal degenerations | |
| TW202242095A (zh) | 安全免疫隱形細胞 | |
| WO2022143694A1 (zh) | 一种针对细胞中单个或多个基因进行基因编辑的方法、产品和应用 | |
| JP4552056B2 (ja) | 後天的免疫寛容の獲得方法 | |
| JPWO2023019203A5 (https=) | ||
| WO2022136215A1 (en) | Safe immuno-stealth cells | |
| CN101305091A (zh) | 分离的髓样骨髓细胞群及用其治疗的方法 | |
| JPWO2023019225A5 (https=) | ||
| Paillard | Tumor-Specific Transgene Expression: An Application for Hepatocarcinoma Gene Therapy The Use of Peripheral Blood Hematopoietic Progenitors for Human Immunodeficiency Virus Gene Therapy |